Position:
Clinical Associate Professor
Division:
General Internal Medicine
Education:
MSc University of Toronto School of Graduate Studies Community Health
MD (Hons) University of Toronto
Recent Publications:
  • Firoz T, Magee LA, Payne BA, Menzies JM, von Dadelszen P for the Pre-eclampsia Integrated Estimate of RiSk (PIERS) Study Group. The PIERS experience: research or quality improvement? JOGC 2012 (in press, MS #11-09-203.R1) [CIHR, MSFHR, CFRI].
  • von Dadelszen P, Dwinnell S, Magee LA, Carleton B, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Payne BA, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN, for the  Research into Advanced Fetal diagnosis and Therapy (RAFT) Group. Response to 2011-LT-10154. BJOG 2012 (MS # 2011-LT-10367, in press).
  • Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. AJOG 2011;Jun 21 [Epub ahead of print] [CIHR, MSFHR, CFRI, Alere International].
  • Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P. Can placental growth factor discriminate between placental intrauterine growth restriction and constitutional intrauterine growth restriction? AJOG 2011 (in press,  MS # W11-0124R1) [CIHR, MSFHR, CFRI, Alere International].
  • Firoz T and Magee LA. Pregnancy is a stress test: the role of the general internist. Can J GIM 2011;6(2):56-8.
  • Khan KS, Borowiack E, Roos C, Kowalska M, Zapalska A, Mol BW, Mignini L, Meads C, Walczak J for the EBM-CONNECT Collaboration (includes Magee LA). Evid Based Med 2011;16(3):65-9.
  • Kozic JR, Benton SJ, Hutcheon JA, Payne BA, Magee LA, von Dadelszen P, for the PIERS Study Group. Abnormal liver function tests as predictors for adverse maternal outcomes in women with preeclampsia. JOGC 2011;33(10):995-1004 [CIHR, MSFHR].
  • Laskin S, Payne B, Hutcheon JA, Qu F, Douglas MJ, Ford J, Lee T, Magee LA, von Dadelszen P, for the PIERS Study Group. The role of platelet counts in the assessment of inpatient women with pre-eclampsia. JOGC 2011;33(9):900-8 [CIHR, MSFHR].
  • Magee LA and Menzies JM on behalf of the CHIPS Study Group. The ClinicalTrials.gov database. Letter to the Editor in response to Zarin DA et al. NEJM 2011;364(9):852-60; NEJM 2011;364(22):2169.
  • Magee LA and von Dadelszen P. Clinical risk prediction of pre-eclampsia. A helpful tool, but not reliable enough to replace traditional methods of detection. BMJ 2011; 342:d1863.
  • Magee LA, Lowe S, Douglas MJ, Kathirgamanathan A. Therapeutics and anaesthesia. Best Pract Res Clin Obstet Gynaecol 2011;25(4):477-90.
  • Magee LA, Massey K, von Dadelszen P,  Fazio M, Payne B, and Liston R for the Canadian Perinatal Network (CPN) Collaborative Group. Identifying potentially eligible subjects for research: paper-based logs vs. the hospital administrative database  Chronic Disease in Canada 2011 (in press, MS # 100909)  [CIHR, MSFHR].
  • Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, Doyle L, Ehman W, Gagnon R, Grobman W, Helewa M, Joseph KS, Martel J, Miller S, Okun N, Rouse D, Senikas V, Sherlock R, Skoll A, Smith G, Wagner B, Wavrant S, Wilson RD, Hutcheon J, and the Maternal Fetal Medicine Committee. SOGC Clinical Practice Guideline: Magnesium sulphate for fetal neuroprotection. JOGC 2011; 33(5):516-29.
  • Magee LA, Sibai B, Easterling T, Walkinshaw S, Abalos E, von Dadelszen P, for the CHIPS Study Group. How to effectively manage hypertension in pregnancy. Br J Clin Pharm 2011;72:3:394-401.
  • Millman AL, Payne B, Qu Z, Douglas MJ, Hutcheon JA, Lee T, Magee LA, Walley KR, von Dadelszen P, for the PIERS Study Group. Oxygen saturation as a predictor of adverse maternal outcomes in women with pre-eclampsia. JOGC 2011;33(7):705-14.
  • Payne B, Magee LA, Menzies J, Côté AM, Hutcheon JA, Kyle P, Li J, Parker C, Pullar B, Walters BN, von Dadelszen P, for the PIERS Study Group. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. JOGC 2011;33(6):588-97.
  • Payne BA, Magee LA, von Dadelszen P. Assessment. surveillance and prognosis. Best Pract Res Clin Obstet Gynaecol 2011;25(4):449-62.
  • Tsigas E and Magee LA. Advocacy organizations as partners in pre-eclampsia progress: patient involvement improves outcomes. Best Pract Res Clin Obstet Gynaecol 2011;25(4):523-36.
  • von Dadelszen P, Dwinnell S, Magee LA, Carleton B, Gruslin A, Lee B, Lim KI, Liston RM, Miller SP, Payne BA, Rurak D, Sherlock RL, Skoll MA, Wareing MM, Baker PN, for the  Research into Advanced Fetal diagnosis and Therapy (RAFT) Group. Sildenafil citrate therapy for early-onset severe intrauterine growth restriction. BJOG 2011;118:624-8.
  • von Dadelszen P, Payne BA, Hutcheon JA, Joseph KS, Magee LA, for the PIERS Study Group. 2011;377(9774):1313. Response to Tajik P, Rengerink K, Ganzevoort W, Zwinderman AH, Mol BW, Bossuyt PM. Prediction of pre-eclampsia complications. Lancet Lancet 2011;377(9774):1314.
  • von Dadeszen P and Magee LA. Hypertensive disorders in pregnancy, Preface to Issue 25.4 of Best Pract Res Clin Obstet Gynaecol 2011;25(4):389-90.
  • Yen TW, Payne B, Qu Z, Hutcheon JA, Lee T, Magee LA, Walters BN, von Dadelszen P, for the PIERS Study Group. Using clinical symptoms to predict adverse maternal and fetal outcomes in women with pre-eclampsia: data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) Study. JOGC 2011;33(8):803-9 [CIHR, MSFHR, CFRI].
  • Côté AM, von Dadelszen P, Ardilouze JL, Magee LA. Microalbuminuria and its role in the hypertensive disorders of pregnancy. Current Hypertension Reviews 2010;6(1):8-19.
  • Gaudet LM, Gruslin A, Magee LA. Weight in pregnancy and its implications – what women report. JOGC 2010;33(3):227-34.
  • Hawkins TL, Gibson PS, Magee LA. The hypertensive disorders of pregnancy: a summary of the 2008 Canadian guidelines. In preparation for the Can J GIM 2010 (in press).
  • Iglesias, MH, Giesbrecht, von Dadelszen, Magee LA. Postpartum hyperkalemia associated with magnesium sulphate. Hypertens Pregn 2010 (in press, MS# LHIP-2009-0055).
  • Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, Brant R, Bujold E, Demianczuk N, Joseph KS, Lee SK, Piedboeuf B, Smith G, Walker M, Whittle W, Wood S, Lee T, Li J, Payne B, and Liston RM for the Canadian Perinatal Network (CPN) Collaborative Group. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22-28 weeks’ gestation. JOGC 2010;33(2):111-20.
  • Xie F, Hu X, Turvey SE, Magee LA, Brunham RM, Choi K-C, Krajden M, Leung PCK, Money DM, Patrick DM, Thomas E, von Dadelszen P. Toll-like receptors 2 and 4 and the cryopryin inflammasome in normal pregnancy and pre-eclampsia. BJOG 2010;117(1):99-108.
  • Xie F, Hu Y, Magee LA, Money DM, Patrick DM, Brunham RM, Thomas E, von Dadelszen for the Toxaemia Group. Chlamydia pneumoniae infection in preeclampsia. Hypertens Pregn 2010 (in press, MS:LHIP-2009-0019) [MSFHR].
  • Xie F, Hu Y, Speert DP, Turvey SE, Peng G, Money DM, Magee LA, von Dadelszen P, for the Toxaemia group. Toll-like receptor gene polymorphisms and preeclampsia risk: a case-control study and data synthesis. Hypertens Pregnancy 2010 (in press). [funding: CIHR, MSFHR, CFRI, STIRRHS].
  • Xu H, Perez-Cuevas R, Xiong X, Reyes H, Julien P, Smith G, von Dadelszen P, Leduc L, Audibert F, Moutquin JM, Piedboeuf B, Shatenstein B, Cabrera SP, Choquette P, Winsor S, Wood S, Benjamin A, Walker M, Helewa M, Dubé J, Tawagi G, Seaward G, Ohlsson A, Magee L, Olatunbosun F, Gratton R, Shear R, Demianczuk, Collet JP, Roy C, Wei S, Fraser W and the INTAPP study group. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). AJOG 2010;202:239.e1-10.
  • Castillo E, Magee LA, Bichet D, Halperin M. Hereditory nephrogenic diabetes insipidus: A major conundrum during labour and delivery. NDT 2009 04 August;doi: 10.1093/ndtplus/sfp098 [MSFHR].
  • Côté AM, Lam EM, von Dadelszen P, Mattman A, Magee LA. Monitoring renal function in hypertensive pregnancy. Hypertens Pregn 2009 Nov27 [Epub ahead of print] (MS# LHIP-2008-0088).
  • Magee L, Sadeghi S. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev 2009;25(1):CD004351.
  • Magee LA for the CHIPS Study Group. The CHIPS Trial (Control of Hypertension In Pregnancy Study) – Protocol (17Mar2009). Lancet 2009 (http://www.thelancet.com/protocol-reviews/09PRT-3980).
  • Magee LA, Sibai BM, Walkinshaw S, Abalos E, von Dadelszen P for the CHIPS Study Group. Special situations in the management of hypertension –  Control of hypertension in pregnancy. Current Hypertension Reports 2009;11:429-36.
  • Magee LA, von Dadelszen P. The management of severe hypertension. In: Severe pre-eclampsia. Eds: Cleary KL and Sibai BM. Semin Perinatol 2009;33(3):138-42 (MSFHR).
  • Magee LA; Yong PJ; Espinosa V Côté AM; Chen I, von Dadelszen P. Expectant management of pre-eclampsia remote from term: A structured systematic review. Hypertens Pregn 2009;25:1-36 (MSFHR).
  • Massey KA, Ansermino M, von Dadelszen P, Morris TJ, Liston RM, Magee LA. What is SNOMED-CT® and why should the ISSHP care? Hypertens Pregn 2009;28(1):119-21 (IWRH, MSFHR).
  • Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Khan SR, Magee LA, Rodgers M . Dalteparin for the prevention of recurrence of severe placental-mediated complications of pregnancy in women without thrombophilia: a pilot a randomized controlled trial.. J Thromb Haemost 2009;7(1):58-64 (MSFHR).
  • von Dadelszen P, Menzies JM, Payne B, Magee LA, Predicting adverse outcomes in women with severe preeclampsia. In: Severe pre-eclampsia. Eds: Cleary KL and Sibai BM. Semin Perinatol 2009;33(3):152-7 [CIHR, WHO, MSFHR].
  • Castillo E, Magee LA, von Dadelszen P, Money D, Blondel-Hill E, van Schalkwyk J. Our patients do not need endocarditis prophylaxis for genitourinary tract procedures: Insights from the 2007 American Heart Association Guidelines. JOGC 2008;30(9):796-799 [MSFHR].
  • Côté AM, Brown MA, Lam EM, von Dadelszen P, Firoz, T, Liston RM, Magee LA. The urinary protein/creatinine ratio is a reasonable diagnostic test for proteinuria in hypertensive pregnancy: A systematic review.  BMJ 2008;336:1003-6 (MSFHR) [Abstracted in Nature Clinical Practice Cardiovascular Medicine  Sept 2008, ACP Journal Club Sept/Oct 2008, and DARE Nov 2008 www.crd.york.ac.uk/CRDWeb] (MSFHR).
  • Côté AM, Lam EM, von Dadelszen P, Mattman A, Magee LA. Twenty-four hour urine collection: gold standard or historical practice? AJOG 2008;199(6):625:e1-6 (MSFHR).
  • Gruslin A, von Dadelszen P, Magee LA on behalf of the Hypertension Guideline Committee. Re: Clinical Practice Guidelines on the Diagnosis, Evaluation and Management of the Hypertensive Disorders of Pregnancy. In response. JOGC 2008;30(11):1000-1 [MSFHR].
  • Koren G, Dugoua JJ, Magee L, Vohra S, Matsui D, Bérard A, Johnson B, Moretti M, Einarson A. MotherNature: establishing a Canadian research network for natural health products (NHPs) during pregnancy and lactation. J Altern Complement Med 2008;14(4):369-72 (MSFHR).
  • Magee LA on behalf of the Hypertension Guideline Committee. Re: Clinical Practice Guidelines on the Diagnosis, Evaluation and Management of the Hypertensive Disorders of Pregnancy. In response. JOGC 2008;30(7):561-2 [MSFHR].
  • Magee LA on behalf of the Hypertension Guideline Committee. Re: Clinical Practice Guidelines on the Diagnosis, Evaluation and Management of the Hypertensive Disorders of Pregnancy. In response. JOGC 2008;30(7):562-3 [MFSHR].
  • Magee LA, Helewa M, Moutquin JM, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can 2008; 30(3 Suppl):S1-48 (SOGC, CHS, MSFHR).
  • Magee LA, Helewa M, Rey E, Côté AM, Douglas J, Gibson P, Gruslin A, Lange I, Leduc L, Logan AG, Smith GN, STIRRHS Pre-eclampsia Scholars (Appendix 1), Cardew S, Firoz T, Moutquin J-M, von Dadelszen P. SOGC Guidelines: Diagnosis, evaluation and management of the hypertensive disorders of pregnancy. JOGC 2008;30(3):Suppl 1 S1-48  (SOGC, CHS, MSFHR).
  • Magee LA, Newstead J, Yarker-Edgar K, Ng J, Côté AM, von Dadelszen P. Pre-eclampsia as a marker of cardiovascular disease. Fetal Mat Med Rev 2008;19(4):271-92.
  • Magee LA, Ramsay G, von Dadelszen P. What is the role of out-of-office BP measurement in hypertensive pregnancy? Hypertens Pregn 2008;27(2):95-101 (MSFHR).
  • Magee LA; Yong PJ; Espinosa V Côté AM; Chen I, von Dadelszen P. Expectant management of pre-eclampsia remote from term: A structured systematic review. Hypertens Pregn (in press, MS# LHIP-2008-0036) [MSFHR].
  • Massey KA Magee LA, Dale S, von Dadelszen P, Claydon J, Morris TJ  Liston RM, and Ansermino JM on behalf of the Canadian Perinatal Network Collaborative Group and the British Columbia Perinatal Health Program. A current landscape of provincial perinatal data collection in Canada. JOGC 2008;31(3):236-46 (IWRH/CIHR, MSFHR).
  • Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Khan S, Magee LA, Rodgers MA . Dalteparin for the prevention of recurrence of severe placental-mediated complications of pregnancy in women without thrombophilia: a randomised controlled trial. J Thromb Haemost 2008 Nov 20 [E pub ahead of print] MS# JTH-2008 00642).
  • von Dadelszen P, Magee LA. What matters in pre-eclampsia are the associated adverse outcomes; the view from Canada. Current Opin Obstet Gynaecol 2008;20:110-115 (MSFHR).
  • Magee LA and von Dadelszen P. Pre-eclampsia and risk revealed. BMJ 2007;335(7627):945-6.
  • Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, Hewson S, Kavuma E, Lee SK, Logan AG, McKay D, Moutquin J-M, Ohlsson A, Rey E, Ross S, Singer J, Willan AR, Hannah ME, for the CHIPS Pilot Trial Collaborative Group. The CHIPS (Control of Hypertension In Pregnancy Study) Pilot Trial. BJOG 2007;114(6):770, e13-20 (CIHR, CFRI, MSFHR).
  • Magee LA, von Dadelszen P, Chan S, Gafni A, Gruslin A, Helewa M, Hewson S, Kavuma E, Lee SK, Logan AG, McKay D, Moutquin J-M, Ohlsson A, Rey E, Ross S, Singer J, Willan AR, Hannah ME, for the CHIPS Pilot Trial Collaborative Group. Women’s views of their experiences in the CHIPS (Control of Hypertension In Pregnancy Study) Pilot Trial. Hypertens Pregn 2007;26:371-87 (CIHR, CFRI, MSFHR).
  • Menzies J, Magee LA, MacNab Y, Li J, Yin R, Stuart H, Baraty B, Lam E, Hamilton T, Lee SK, von Dadelszen P for the PIERS Study Group. Instituting guidelines is associated with a reduced incidence of adverse outcomes in women with pre-eclampsia: a single site study. Obstet Gynecol 2007;110:121-7 (CIHR, CFRI, MSFHR).
  • Menzies J, Magee LA, MacNab YC, Ansermino JM, Li J, Douglas MJ, Gruslin A, Kyle P, Lee SK, Moore MP, Moutquin JM, Smith GN, Walker JJ, Walley KR, Russell JA, von Dadelszen P. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregn 2007;26:447-62 (CIHR, CFRI, MSFHR).
  • Newstead J, von Dadelszen P, Magee LA. Pre-eclampsia and future cardiovascular risk. Expert Review of Cardiovascular Therapy 2007;5(2):283-94 (MSFHR).
  • von Dadelszen P, Menzies J, Gilgoff S, Xie F, Douglas MJ, Sawchuck D, Magee LA. Evidence-based management for preeclampsia. Frontiers in Bioscience 2007;12:2876-89.
  • Magee L, Shrim A, Koren G. Diagnosis and management of nausea and vomiting in pregnancy. Fet Mat Med Rev 2006;17:45-67.
  • Sherwin JE, Lockitch G, Rosenthal P, Ashwood ER, Geaghan S, Magee L, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: maternal-fetal risk assessment and reference values in pregnancy. Washington, DC: AACC Press, 2006 (www.nacb.org).